Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-24
DOI
10.1007/s00432-021-03633-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- CD20 + tumor‐infiltrating immune cells and CD204 + M2 macrophages are associated with prognosis in thymic carcinoma
- (2020) Jun Sato et al. CANCER SCIENCE
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer
- (2019) Pauline L. Pfuderer et al. BRITISH JOURNAL OF CANCER
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers
- (2019) Yuji Eso et al. JOURNAL OF GASTROENTEROLOGY
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
- (2019) Roy S Herbst et al. LANCET ONCOLOGY
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development
- (2018) David G. Hill et al. INTERNATIONAL JOURNAL OF CANCER
- Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma
- (2018) Anna Maria Wirsing et al. MODERN PATHOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gastric Cancer Etiology and Management in Asia and the West
- (2018) Ashley E. Russo et al. Annual Review of Medicine
- The safety of apatinib for the treatment of gastric cancer
- (2018) Ruixuan Geng et al. Expert Opinion On Drug Safety
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- A molecular portrait of microsatellite instability across multiple cancers
- (2017) Isidro Cortes-Ciriano et al. Nature Communications
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
- (2015) X.-D. Liu et al. Cancer Immunology Research
- High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression
- (2015) Diana Costa Bento et al. OncoImmunology
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma
- (2013) Gabriela Avram et al. HISTOPATHOLOGY
- High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin -Producing Dendritic Cells in Human Breast Cancer
- (2013) L. Martinet et al. JOURNAL OF IMMUNOLOGY
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer
- (2011) L. Martinet et al. CANCER RESEARCH
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules
- (2011) Christine Moussion et al. NATURE
- INTERFEROME: the database of interferon regulated genes
- (2008) Shamith A. Samarajiwa et al. NUCLEIC ACIDS RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More